PSA-20 – Polysialic acid for the treatment of neurodegenerative diseases

There is no satisfactory therapy to prevent the loss of synapses, axons or neurons in neurodegenerative diseases, such as senile macular degeneration, multiple sclerosis and Alzheimer’s disease. Several studies demonstrate that this neuronal damage is partly mediated by proinflammatory cytokines released by tissue macrophages and by reactive oxygen species. The present invention allows preventing the production of proinflammatory cytokines and reactive oxygen species through the application of low molecular weight polysialic acid PSA-20. In vitro studies showed that PSA-20 prevents the activation of human macrophages and human microglia thereby inhibiting the production of cytotoxic proinflammatory cytokines and reactive oxygen species. It has been shown, that this anti-inflammatory effect is mediated through the human lineage specific receptor Siglec-11.

Weitere Informationen: PDF

PROvendis GmbH
Tel.: +49 (0)208/94105 10

Ansprechpartner
Dipl.-Ing. Alfred Schillert